Team

Our team brings together proven leaders with diverse experiences and deep expertise across all aspects of a successful biotech company. We are united by a belief in the transformative potential of gene therapy and by our steadfast commitment to making a difference in the lives of children and families affected by rare disease.

Leadership
member image alt text
John Cerio
SVP & Global Head of Human Resources
We are building a highly collaborative culture with a deep understanding and appreciation of our diverse talents and collective strengths, and an abiding commitment to our mission to potentially transform the lives of families affected by rare disease.

John brings over 25 years of human resource (HR) leadership experience in the pharmaceutical and biotech industry building high growth, high performance, mission-driven and entrepreneurial companies. Most recently, John served as vice president of human resources and administration for Agenus, where he led the HR function through periods of rapid growth, transformation and global expansion. John played a key role in leading the acquisition and integration of 4-antibody AG and the build-out of the company’s R&D and technical operations capabilities responsible for generating and advancing an immuno-oncology portfolio of over a dozen clinical candidates. Prior to Agenus, John was vice president of global HR for PerkinElmer Life Sciences, during which time the company more than doubled in size and annual sales and significantly expanded its commercial business and operations in the U.S., Europe and APAC regions. Earlier in his career, he spent nearly 10 years with Bristol-Myers Squibb in a series of progressively responsible HR leadership roles including director of HR for corporate staff, director of organizational development for U.S. medicines and head of HR for the oncology and immunology division.

John earned his B.S. in industrial and labor relations from Cornell and his M.A. in organizational psychology from Columbia with a concentration in organizational development. He also completed the global leadership development program at the London Business School.

member image alt text
Anne Dupraz-Poiseau, Ph.D.
Chief Regulatory Officer
We will always be confronted by obstacles in life. The important thing is being open to new routes to meet our goals and going beyond our limitations. This is what Orchard is working towards: developing the medicines of tomorrow, which might previously have been seen as impossible, but will potentially be standards of care in the future.

Anne has 25 years of experience tackling R&D, clinical and regulatory challenges for global development within medtech and biotech companies. Anne joined Orchard Therapeutics in 2016 to lead global regulatory strategy and devise innovative and expedited pathways for the development and the registration of Orchard’s HSC gene therapies. She built and manages an international, highly-trained and experienced regulatory team. Prior to joining Orchard Therapeutics, she was executive vice president at Voisin Consulting Life Sciences (VCLS), an international consulting firm highly experienced in orphan drug development. In her leadership role, Anne was actively involved in the design, preparation and management of a high number of successful regulatory submissions at all stages of product development. Anne had a pioneering role in the field of advanced therapies and managed over 50 different tissue, cell and gene-based therapy development programs. Over the years, Anne has established strong communication links with regulators, including the Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the European Member States’ medicine agencies. Bringing together scientific and regulatory expertise in the Advanced Therapies Medicinal Products (ATMPs) area, Anne actively participated in the elaboration of the European ATMP Regulation through industry associations and worked closely with the EMA on related guidelines. Before joining VCLS, Anne co-founded the regulatory consulting firm Meditest International. Anne began her career as a research & development project manager for Medtronic Sofamor-Danek.

Anne earned a joint Ph.D. in biomaterials and artificial organs from the University of Dental Surgery in Nantes, France, the Free University of Berlin, Germany, and the University of Medicine of Leiden, Netherlands, working on the development and evaluation of drug-device combination products aimed at bone substitution.

member image alt text
Adrien Lemoine
Chief Business Officer
Orchard’s technology and industry-leading pipeline of potentially curative gene therapies offers the opportunity to transform the lives of patients while potentially revolutionizing medicine.

Adrien brings nearly 20 years of experience creating value for pharma and biotech companies. His responsibilities at Orchard Therapeutics include overseeing business development, program management, program leadership and portfolio strategy for the company. Since joining Orchard in October 2016, he has led the build-out of Orchard’s industry-leading gene therapy pipeline through multiple in-licensing deals, notably the acquisition of GSK’s gene therapy portfolio in April 2018. Prior to joining Orchard, Adrien was executive director, corporate strategy and development at AstraZeneca where he led M&A activities as well as successful out-licensing, divestments and new company spinoff projects. He also served as a member of Corvidia Therapeutics’ board of directors. Prior to AstraZeneca, Adrien spent nine years at GSK; his most recent role was strategy & operations director in the rare disease unit, working in particular on GSK’s ex vivo autologous HSC gene therapy portfolio. He was a member of the advisory committee for Kurma BioFund II, a venture capital fund with a special focus on rare diseases. His experience at GSK also encompasses European and global roles of increasing seniority in R&D portfolio strategy and commercial analysis. He started his career as a strategy consultant at Alcimed in Paris, France, supporting the development of biotechnology startup companies. 

Adrien holds an engineering degree from Supélec in Paris and a M.Sc. in engineering and physical science in medicine from Imperial College in London.

member image alt text
Kathryn Payne
SVP, Corporate Communications & External Affairs
I’m inspired to be part of an organization that goes above and beyond for the benefit of patients, families and all those affected by rare diseases. With gene therapy, we have a unique opportunity to potentially stop these devastating conditions in their tracks.

Katie brings nearly 20 years of communications, stakeholder engagement and health policy expertise to Orchard Therapeutics as senior vice president of corporate communications and external affairs. Her responsibilities at Orchard include directing the company’s internal and external communications, patient advocacy, investor relations and government relations functions. Katie joined Orchard from AMAG Pharmaceuticals, where she served as senior vice president of corporate affairs, overseeing all communications, public affairs and advocacy activities. During her time at AMAG, Katie led the internal and external communications strategy for six significant corporate and business development transactions and played a key role in the company’s efforts to collaborate with healthcare experts and advocacy groups to advance public health and achieve key public affairs outcomes. Her expertise includes stakeholder engagement, issues and crisis management, media relations and corporate identity. Prior to AMAG, Katie spent a decade at a global communications and public affairs firm where she developed and implemented U.S. and global communications programs for a wide variety of companies and organizations in the healthcare and biopharmaceutical field. She also served in communications roles at The World Bank in Washington, D.C. and Forrester Research.

Katie graduated Phi Beta Kappa and with high honors from Johns Hopkins University with a B.A. in writing and business management and a master’s degree in communications. She currently serves as a member of the MassBio board of directors and is also a member of the board of directors of the Boston-Manchester March of Dimes chapter.

member image alt text
Andrea Spezzi, M.D.
Chief Medical Officer
From my days as a pediatrician, helping children with severe diseases has been my life’s purpose. Delivering potentially transformative products would be the culmination of many years of collective work and our mission to give back to families, science and society as a whole.

Andrea brings extensive experience and expertise in the development and execution of all aspects of clinical development, particularly in pediatric rare diseases. Prior to co-founding Orchard Therapeutics, Andrea served as vice president and medicine development leader at the GSK rare diseases unit, and before that as senior medical director at the immune inflammation discovery performance unit. Before GSK, Andrea was global medical director R&D at Takeda in the metabolic and cardiovascular area and in charge of the pediatric developments for Takeda Europe R&D. She previously worked as a research physician at Hammersmith Medicines Research. Before moving to the pharmaceutical industry, Andrea practiced as a pediatrician for 12 years in Argentina, Spain, and the UK. Andrea was recognized as one of 2018’s “Fiercest Women in Life Sciences” by FiercePharma and as one of BioBeat’s “50 Movers & Shakers in BioBusiness” in 2017. 

Andrea obtained her medical degree from the University of Buenos Aires (UBA) and completed residency in pediatrics and postgraduate training in pediatric immunology at the Dr. Elizalde Children’s Hospital in Buenos Aires, Argentina. Andrea also obtained a specialist in pharmaceutical medicine degree from University of Basel, Switzerland. She is a fellow of the Faculty of Pharmaceutical Medicine (FFPM) in London.

member image alt text
Frank Thomas
Chief Operating Officer & Chief Financial Officer
As a leader in gene therapy, I believe we should be providing innovative solutions across the continuum of a fully-integrated company – from designing adaptive clinical studies to developing some of the most advanced technologies to manufacture and deliver medicines – all while supporting revolutionary ways to improve access to treatment.

Frank brings nearly 20 years of experience in the biopharmaceutical industry as an accomplished financial and business executive. He has a background in developing and executing capital markets strategies for private and public companies, as well as experience in operations management, corporate strategy and business development. Frank previously served as president and chief operating officer of AMAG Pharmaceuticals, where he helped develop the business from a single product company in 2011 to one with a portfolio of commercial and development-stage products that generated more than $600 million in sales in 2017. During that time, Frank raised more than $1.8 billion in new capital to support AMAG’s growth strategy. Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, Inc. Earlier in his career, Frank also served as chief executive officer for Critical Therapeutics and chief financial officer for Esperion Therapeutics. Each company completed its initial public offering in the U.S. during his tenure. Frank currently serves on the board of directors of Zafgen and Spero Therapeutics. 

Frank received his B.S. in business administration from the University of Michigan, Ann Arbor.

`
Board of Directors

The site uses cookies to provide you with a more responsive and personalized service. By using this site, you agree to our use of cookies as set out in our cookie policy.

Please read our privacy policy and cookie policy for more information on the cookies we use and how to delete or block the use of cookies.